The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 15, 2020
Filed:
Mar. 30, 2017
Applicant:
GE Healthcare Bioprocess R&d Ab, Uppsala, SE;
Inventors:
Jean-Luc Maloisel, Uppsala, SE;
Tobias Söderman, Uppsala, SE;
Ola Lind, Uppsala, SE;
Ida Eklind, Uppsala, SE;
Assignee:
Cytiva BioProcess R&D AB, Uppsala, SE;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
B01D 15/32 (2006.01); B01D 15/36 (2006.01); B01D 15/38 (2006.01); B01J 20/26 (2006.01); B01J 20/286 (2006.01); B01J 20/289 (2006.01); B01J 20/32 (2006.01); B01J 39/07 (2017.01); B01J 39/26 (2006.01); B01J 41/07 (2017.01); B01J 41/13 (2017.01); B01J 41/20 (2006.01); B01J 47/02 (2017.01); C07K 1/18 (2006.01); C07K 16/00 (2006.01); B01J 39/19 (2017.01);
U.S. Cl.
CPC ...
B01J 47/02 (2013.01); B01D 15/327 (2013.01); B01D 15/362 (2013.01); B01D 15/363 (2013.01); B01D 15/3809 (2013.01); B01D 15/3847 (2013.01); B01J 20/267 (2013.01); B01J 20/286 (2013.01); B01J 20/289 (2013.01); B01J 20/3208 (2013.01); B01J 20/3217 (2013.01); B01J 20/3219 (2013.01); B01J 20/3278 (2013.01); B01J 20/3285 (2013.01); B01J 20/3293 (2013.01); B01J 39/07 (2017.01); B01J 39/19 (2017.01); B01J 39/26 (2013.01); B01J 41/07 (2017.01); B01J 41/13 (2017.01); B01J 41/20 (2013.01); C07K 1/18 (2013.01); B01D 15/361 (2013.01); B01D 15/3804 (2013.01); B01J 2220/54 (2013.01); C07K 16/00 (2013.01);
Abstract
The invention discloses a separation matrix for purification of biomacromolecules, comprising a plurality of particles () having a core region () and a shell region (), wherein: a) said shell region is accessible to a target biomacromolecule; b) said core region is less accessible to the target biomacromolecule than the shell region; and c) the core region comprises a grafted polymer comprising residues of at least one polymerizable monomer.